Hybridization LC-MS/MS Workflow to Quantify an siRNA Drug Candidate in Plasma, CSF, and Tissues
ISSUE NO. 31 — The Advantages of Conducting Early-Phase Clinical Research in Canada
Timely completion of necessary studies is a critical element of drug development, bringing important treatments to patients in a safe and cost-efficient way. A consideration with a measurable impact on early-phase clinical studies is the location where trials are performed; this is especially true for first-in-human (FIH) trials.
Conducting early-phase clinical research on novel compounds in Canada can provide significant advantages versus other locations.
In Issue 31 of The Altascientist, we take a deep dive into these advantages, covering:
- Canadian CTA trials–time and cost savings
- Regulatory review process predictability
- Business efficiency cost savings
- Clinical trial participants
Scratching the Surface of Dermal Testing
Dr. Keyhani Reflects on International Day of Women and Girls in Science
Opinion | A Day to Celebrate, and a Call to Action
Dr.
Case Study―Evaluating Milling Conditions for Scaling Up a Nanosuspension Drug Product
New Generation Pain Relief Without Opioids
Opioids are highly effective at relieving both acute and chronic pain. However, this benefit comes at a significant cost: they are also highly addictive.
2022 Year in Review
|